Are MDCK Cells Transfected with the Human MDR1 Gene a Good Model of the Human Intestinal Mucosa?

AbstractPurpose. To investigate whether Madin-Darby canine kidney cells transfected with the human MDR1 gene (MDCK-MDR1) are a good model of the human intestinal mucosa. Methods. P-glycoprotein (P-gp) expression in Caco-2 cells was compared with P-gp expression in MDCK wild- type (MDCK-WT) and MDCK-MDR1 cells using Western blotting methods. The polarized efflux activities of P-gp(s) in MDCK-MDR1 cells, MDCK-WT cells, and Caco-2 cells were compared using digoxin as a substrate. Apparent Michaelis-Menten constants (KM,Vmax) for the efflux of vinblastine in these three cell lines were determined. Apparent inhibition constants (KI) of known substrates/inhibitors of P-gp were determined by measuring their effects on the efflux of digoxin in Caco-2 or MDCK-MDR1 cell monolayers. Results. MDCK-MDR1 cells expressed higher levels of P-gp compared to Caco-2 and MDCK-WT cells, as estimated by Western blots. Two isoforms of P-gp were expressed in Caco-2 and MDCK cells migrating with molecular weights of 150 kDa and 170 kDa. In MDCK-MDR1 cells, the 150 kDa isoforms appeared to be overexpressed. The MDCK-MDR1 cells exhibited higher polarized efflux of [3H]-digoxin than did Caco-2 and MDCK-WT cells. KM values of vinblastine in Caco-2, MDCK-WT, and MDCK-MDR1 cells were 89.2 ± 26.1, 24.5 ± 1.1, and 252.8 ± 134.7 μM, respectively, whereas Vmax values were 1.77 ± 0.22, 0.42 ± 0.01, and 2.43 ± 0.86 pmolcm−2s−1, respectively. Known P-gp substrates/inhibitors showed, in general, lower KI values for inhibition of digoxin efflux in Caco-2 cells than in MDCK-MDR1 cells. Conclusions. These data suggest that the MDCK-MDR1 cells overexpress the 150 kDa isoform of P-gp. MDCK-MDR1 cells are a useful model for screening the P-gp substrate activity of drugs and drug candidates. However, the apparent kinetics constants and affinities of substrates determined in the MDCK-MDR1 cell model may be different than the values obtained in Caco-2 cells. These differences in substrate activity could result from differences in the relative expression levels of total P-gp in Caco-2 and MDCK-MDR1 cells and/or differences in the partitioning of substrates into these two cell membrane bilayers.

[1]  F. Sharom,et al.  Characterization of the ATPase activity of P-glycoprotein from multidrug-resistant Chinese hamster ovary cells. , 1995, The Biochemical journal.

[2]  F. Sharom,et al.  The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. , 1999, Biochemistry.

[3]  L. Reuss,et al.  Unidirectional fluxes of rhodamine 123 in multidrug-resistant cells: evidence against direct drug extrusion from the plasma membrane. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[4]  I. Schoots,et al.  Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in MRP2-deficient rats. , 2001, Molecular pharmacology.

[5]  P. Borst,et al.  Multidrug resistance and the role of P-glycoprotein knockout mice. , 1995, European journal of cancer.

[6]  C. Higgins,et al.  The functional purification of P-glycoprotein is dependent on maintenance of a lipid-protein interface. , 1997, Biochimica et biophysica acta.

[7]  G. Meer,et al.  Two strains of the Madin‐Darby canine kidney (MDCK) cell line have distinct glycosphingolipid compositions. , 1986, The EMBO journal.

[8]  J. Seelig,et al.  Partitioning of local anesthetics into membranes: surface charge effects monitored by the phospholipid head-group. , 1988, Biochimica et biophysica acta.

[9]  L. Benet,et al.  Active secretion and enterocytic drug metabolism barriers to drug absorption. , 2001, Advanced drug delivery reviews.

[10]  B. Rothen‐Rutishauser,et al.  P-Glycoprotein in cell cultures: a combined approach to study expression, localisation, and functionality in the confocal microscope. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[11]  J. Riordan,et al.  Multidrug-resistance phenotype in Chinese hamster ovary cells. , 1983, Cancer treatment reports.

[12]  A. Read Genes IV , 1990 .

[13]  M. Ichise,et al.  Comparison of the accumulation and efflux kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line , 2000, European Journal of Nuclear Medicine.

[14]  R. Conradi,et al.  Evidence for a polarized efflux system for peptides in the apical membrane of Caco-2 cells. , 1993, Biochemical and biophysical research communications.

[15]  J. Tolan,et al.  MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. , 1999, Journal of pharmaceutical sciences.

[16]  J. R. Sportsman,et al.  Association of intestinal peptide transport with a protein related to the cadherin superfamily. , 1994, Science.

[17]  R. Evers,et al.  Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. , 1996, The Journal of clinical investigation.

[18]  Y. Sawada,et al.  Transport of digoxin into brain microvessels and choroid plexuses isolated from guinea pig. , 1988, Journal of pharmaceutical sciences.

[19]  I. Pastan,et al.  Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. , 1990, The Journal of biological chemistry.

[20]  J. H. Beijnen,et al.  Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.

[21]  H. Melhus,et al.  Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. , 2001, The Journal of pharmacology and experimental therapeutics.

[22]  T. Cantz,et al.  Expression of the apical conjugate export pump, Mrp2, in the polarized hepatoma cell line, WIF‐B , 1998, Hepatology.

[23]  R. Borchardt The application of cell culture systems in drug discovery and development. , 1995, Journal of drug targeting.

[24]  J Ferté,et al.  Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. , 2000, European journal of biochemistry.

[25]  P Langguth,et al.  P-Glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels. , 1998, Journal of pharmaceutical sciences.

[26]  R. Borchardt,et al.  A Functional Assay for Quantitation of the Apparent Affinities of Ligands of P-Glycoprotein in Caco-2 Cells , 2001, Pharmaceutical Research.

[27]  I. Pastan,et al.  Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates. , 1994, Molecular pharmacology.

[28]  D. Keppler,et al.  Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. , 1999, Biochimica et biophysica acta.

[29]  K. Bock,et al.  Coordinate induction by antioxidants of UDP-glucuronosyltransferase UGT1A6 and the apical conjugate export pump MRP2 (multidrug resistance protein 2) in Caco-2 cells. , 2000, Biochemical pharmacology.

[30]  M Rowland,et al.  Dose-dependent pharmacokinetics of cyclosporin A in rats: events in tissues. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[31]  V. Ling,et al.  P-glycoprotein-mediated Hoechst 33342 transport out of the lipid bilayer. , 1997, European journal of biochemistry.

[32]  P. Borst,et al.  Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Thomas J. Vidmar,et al.  The Madin Darby Canine Kidney (MDCK) Epithelial Cell Monolayer as a Model Cellular Transport Barrier , 2004, Pharmaceutical Research.

[34]  T. Walle,et al.  Transport of the flavonoid chrysin and its conjugated metabolites by the human intestinal cell line Caco-2. , 1999, Biochemical pharmacology.

[35]  Y. Sugiyama,et al.  Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[36]  R. Borchardt,et al.  Characterization of the Efflux Transporter(s) Responsible for Restricting Intestinal Mucosa Permeation of the Coumarinic Acid-Based Cyclic Prodrug of the Opioid Peptide DADLE , 2002, Pharmaceutical Research.

[37]  Per Artursson,et al.  Intestinal Drug Absorption and Metabolism in Cell Cultures: Caco-2 and Beyond , 1997, Pharmaceutical Research.

[38]  A. Waseem Malick,et al.  The use of the intestinal epithelial cell culture model, Caco-2, in pharmaceutical development , 1996 .

[39]  A. Smith,et al.  Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum. , 1998, Journal of the National Cancer Institute.

[40]  B. Sikic,et al.  MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells , 2000, British Journal of Cancer.

[41]  W. Lamers,et al.  Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport , 1985, Hepatology.

[42]  T. Litman,et al.  Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. , 1999, Cancer letters.

[43]  K. Brouwer,et al.  Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[44]  C. Vergely,et al.  In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. , 1993, Cancer research.

[45]  K. Luthman,et al.  Caco-2 monolayers in experimental and theoretical predictions of drug transport. , 2001, Advanced drug delivery reviews.

[46]  G. van Meer,et al.  Sorting of newly synthesized galactosphingolipids to the two surface domains of epithelial cells , 1996, The Journal of cell biology.

[47]  James E. Polli,et al.  Influence of Passive Permeability on Apparent P-glycoprotein Kinetics , 2000, Pharmaceutical Research.

[48]  A. Giuliano,et al.  SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells. , 1999, Cancer research.

[49]  M. Kool,et al.  Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. , 1998, The Journal of clinical investigation.

[50]  M. Takano,et al.  Relationship between expression level of P-glycoprotein and daunorubicin transport in LLC-PK1 cells transfected with human MDR1 gene. , 1997, Biochemical pharmacology.

[51]  U. Christians,et al.  Active transport of the angiotensin‐II antagonist losartan and its main metabolite EXP 3174 across MDCK‐MDR1 and Caco‐2 cell monolayers , 2000, British journal of pharmacology.

[52]  T. Tsuruo,et al.  Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. , 1993, The Journal of biological chemistry.

[53]  V. H. Lee,et al.  Age-dependent Expression of P-Glycoprotein gp17O in Caco-2 Cell Monolayers , 1996, Pharmaceutical Research.

[54]  M. Kool,et al.  The multidrug resistance protein family. , 1999, Biochimica et biophysica acta.

[55]  F. Sharom,et al.  Interaction of P-glycoprotein with defined phospholipid bilayers: a differential scanning calorimetric study. , 1997, Biochemistry.

[56]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.

[57]  D. Keppler,et al.  ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. , 1997, The Biochemical journal.

[58]  R. Evers,et al.  Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1 , 1997, FEBS letters.

[59]  Y Zhang,et al.  Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. , 1999, Journal of controlled release : official journal of the Controlled Release Society.